fosamprenavir has been researched along with nevirapine in 7 studies
Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (nevirapine) | Trials (nevirapine) | Recent Studies (post-2010) (nevirapine) |
---|---|---|---|---|---|
174 | 55 | 37 | 3,212 | 509 | 1,108 |
Protein | Taxonomy | fosamprenavir (IC50) | nevirapine (IC50) |
---|---|---|---|
Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Reverse transcriptase/ribonuclease H | Human immunodeficiency virus 1 | 1.165 | |
Prothrombin | Bos taurus (cattle) | 1.15 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 BH10 | 1.4504 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 2.05 | |
Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 1.4353 | |
Imidazoleglycerol-phosphate dehydratase | Saccharomyces cerevisiae S288C | 1.7 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.181 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 0.181 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.69 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.7 | |
Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 5.75 | |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.18 | |
Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 2.071 | |
Protease | Human immunodeficiency virus 1 | 0.101 | |
Reverse transcriptase | Human immunodeficiency virus 1 | 3.995 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Boyle, BA | 1 |
Girault, V | 1 |
DeJesus, E; Lou, Y; Masterman, A; Min, SS; Piliero, PJ; Shelton, MJ; Stein, DS; Summers, K; Wire, MB | 1 |
Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F | 1 |
Bocchiola, B; Cahua, T; Castagna, A; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Panzini, P; Pazzi, A; Salpietro, S; Zandonà, D | 1 |
Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
3 review(s) available for fosamprenavir and nevirapine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
[The treatment of HIV infection].
Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Sulfonamides; Tenofovir; Zidovudine | 2005 |
1 trial(s) available for fosamprenavir and nevirapine
Article | Year |
---|---|
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2006 |
3 other study(ies) available for fosamprenavir and nevirapine
Article | Year |
---|---|
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; France; Furans; HIV Infections; Humans; Male; Models, Biological; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2008 |
Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Furans; HIV Infections; Humans; Italy; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Oxazines; Pyridines; Self Report; Sulfonamides; Surveys and Questionnaires; Viral Load | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |